WO2023039175A3 - Predictors of achromatopsia treatment efficacy - Google Patents

Predictors of achromatopsia treatment efficacy Download PDF

Info

Publication number
WO2023039175A3
WO2023039175A3 PCT/US2022/043077 US2022043077W WO2023039175A3 WO 2023039175 A3 WO2023039175 A3 WO 2023039175A3 US 2022043077 W US2022043077 W US 2022043077W WO 2023039175 A3 WO2023039175 A3 WO 2023039175A3
Authority
WO
WIPO (PCT)
Prior art keywords
achromatopsia
predictors
treatment efficacy
subject
treatment
Prior art date
Application number
PCT/US2022/043077
Other languages
French (fr)
Other versions
WO2023039175A2 (en
Inventor
Mauro GOLDBAUM
Original Assignee
Applied Genetic Technologies Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Genetic Technologies Corporation filed Critical Applied Genetic Technologies Corporation
Publication of WO2023039175A2 publication Critical patent/WO2023039175A2/en
Publication of WO2023039175A3 publication Critical patent/WO2023039175A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/102—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for optical coherence tomography [OCT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides methods for treating or selecting a subject for treatment of a retinal disease or disorder, including, without limitation, achromatopsia (ACHM), based on an analysis of the subject's retinal structure and/or function.
PCT/US2022/043077 2021-09-09 2022-09-09 Predictors of achromatopsia treatment efficacy WO2023039175A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163242448P 2021-09-09 2021-09-09
US63/242,448 2021-09-09

Publications (2)

Publication Number Publication Date
WO2023039175A2 WO2023039175A2 (en) 2023-03-16
WO2023039175A3 true WO2023039175A3 (en) 2023-04-27

Family

ID=85506810

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/043077 WO2023039175A2 (en) 2021-09-09 2022-09-09 Predictors of achromatopsia treatment efficacy

Country Status (1)

Country Link
WO (1) WO2023039175A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140364486A1 (en) * 2013-05-16 2014-12-11 Guo-jie Ye Promoters, expression cassettes, vectors, kits, and methods for the treatment of achromatopsia and other diseases
US20200392536A1 (en) * 2018-01-12 2020-12-17 Ucl Business Ltd Compositions and Methods for Treating Retinal Disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140364486A1 (en) * 2013-05-16 2014-12-11 Guo-jie Ye Promoters, expression cassettes, vectors, kits, and methods for the treatment of achromatopsia and other diseases
US20200392536A1 (en) * 2018-01-12 2020-12-17 Ucl Business Ltd Compositions and Methods for Treating Retinal Disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FAHIM ET AL.: "Diagnostic Fundus Autofluorescence Patterns in Achromatopsia", AMERICAN JOURNAL OF OPHTHALMOLOGY, vol. 156, no. 6, 2013, pages 1211 - 1219, XP028773804, DOI: 10.1016/j.ajo.2013.06.033 *
GREENBERG JONATHAN P., SHERMAN JEROME, ZWEIFEL SANDRINE A., CHEN ROYCE W. S., DUNCKER TOBIAS, KOHL SUSANNE, BAUMANN BRITTA, WISSIN: "Spectral-Domain Optical Coherence Tomography Staging and Autofluorescence Imaging in Achromatopsia", JAMA OPHTHALMOLOGY, AMERICAN MEDICAL ASSOCIATION, US, vol. 132, no. 4, 1 April 2014 (2014-04-01), US , pages 437, XP093064735, ISSN: 2168-6165, DOI: 10.1001/jamaophthalmol.2013.7987 *
LI DANJIE, KISHI SHOJI: "Loss of Photoreceptor Outer Segment in Acute Zonal Occult Outer Retinopathy", ARCHIVES OF OPHTHALMOLOGY, AMERICAN MEDICAL ASSOCIATION, UNITED STATES, vol. 125, no. 9, 1 September 2007 (2007-09-01), United States , pages 1194, XP093064738, ISSN: 0003-9950, DOI: 10.1001/archopht.125.9.1194 *

Also Published As

Publication number Publication date
WO2023039175A2 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
WO2018112446A3 (en) Use of apoe4 motif-mediated genes for diagnosis and treatment of alzheimer's disease
AU2019262220A8 (en) Methods of diagnosing and treating based on site-specific tau phosphorylation
EP4338662A3 (en) Predictive therapy neurostimulation systems
AP1750A (en) Methods for treating ocular neovascular diseases
WO2021048619A3 (en) Biomarkers and treatments of alzheimer's disease and mild cognitive impairment
WO2006113890A3 (en) System for indication-based medical device programming
AU2002366641A1 (en) Methods for inhibiting ocular processes
TW200528117A (en) Methods and reagents for the treatment of proliferative diseases
WO2005067956A3 (en) Use of interleukin-21 for the treatment of autoimune diseases and allograft rejection
EA201892803A1 (en) ANTI-TUMOR THERAPY
WO2020154268A3 (en) Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors
WO2002063005A3 (en) Lipid-associated molecules
WO2020080865A3 (en) Magnetic field stimulator-equipped massage device and method for preventing and treating brain disorders such as dementia or depression
AU2020225197A8 (en) Piezo type mechanosensitive ion channel component 1 (PIEZO1) variants and uses thereof
WO2023039175A3 (en) Predictors of achromatopsia treatment efficacy
WO2019157527A3 (en) Methods related to parkinson's disease and synucleinopathies
WO2001096598A3 (en) cDNA FOR HUMAN METHYLENETETRAHYDROFOLATE REDUCTASE AND USES THEREOF
WO2003016497A3 (en) Molecules for disease detection and treatment
WO2023235838A3 (en) Rna-targeting splicing modifiers for treatment of foxp3-associated conditions and diseases
WO2004039321A8 (en) Combinative nicotinic/d1 agonism therapy for the treatment of alzheimer’s disease
WO2005101000A3 (en) Human glycoprotein hormone superagonists and uses thereof
MX2022002629A (en) Rebamipide for use in prevention and treatment of crohn's disease.
WO2003052049A3 (en) Molecules for disease detection and treatment
KR102080591B1 (en) Method for curing tinnitus based on virtual reality
WO2023129531A3 (en) Methods for diagnosing and/or treating alzheimer's disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22868123

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE